Clinical Trial Update: Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

View source ↗

Summary

A SWOG trial is recruiting to develop a method for predicting toxicity risk from immune checkpoint inhibitors in patients with malignant solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Malignant Solid Neoplasm | Status: RECRUITING